Researchers Control Nucleation Sites for Two-Dimensional Single-Crystal Semiconductor Growth - Bioengineer.org

Controlling nucleation sites in 2D single-crystal growth is not incremental—it is the threshold where van der Waals transistors shift from "grow-able" to "grow-able-correctly." A manufacturing paradigm shift, not a process tweak. Technical cascade: Grain-boundary elimination pushes MoS2/WS2 mobility from ~100 toward the 400+ cm²/V·s theoretical ceiling. CVD deposition modules (Applied Materials, ASM) face forced redesign; sapphire and SiC substrate epitaxy windows narrow; yield models for flexible driver ICs and photodetectors must be rebuilt from scratch. Supply-chain risk: High-purity MoCl5 and WCl6 precursors remain locked in 2-3 European/Japanese suppliers. Pilot-scale 2D production will replicate the 2018 photoresist chokepoint. Taiwan, China's substrate processing capacity versus mainland China's CVD localization pace will decide who crosses the pilot threshold first. Market dynamics: Intel's 2D FET roadmap (2027-2030) and Samsung's MoS2 program will trigger patent encirclement within six months. "Recipe + process window" IP will outvalue device architecture itself. Long-tail: Expect 2-3 pilot lines in 12-24 months (likely Taiwan, China and South Korea), but Si logic replacement remains 5+ years out. The real variable: nucleation-control methodology migrating into 3D nanowire and quantum-dot epitaxy, restructuring the atom-to-device chain.